Drug details

Epkinly (epcoritamab-bysp injection)

type of Antineoplastics, Anti-CD20 Monoclonal Antibodies

Epkinly (epcoritamab-bysp) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

This drug may have the following side effects:

• nausea,
• diarrhea,
• fever,
• musculoskeletal pain,
• fatigue,
• abdominal pain,
• injection site reactions,
• decreased white blood cells,
• decreased hemoglobin, and
• decreased platelets.
• cytokine release syndrome,

The following drugs are related to Epkinly, either as a replacement or used together:

• YESCARTA (axicabtagene ciloleucel suspension for intravenous infusion)
• Blincyto (blinatumomab for injection)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Monjuvi (tafasitamab-cxix injection)
• Polivy (polatuzumab vedotin-piiq for injection)
• Riabni (rituximab-arrx injection)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Truxima (rituximab-abbs injection)
• Ruxience (rituximab-pvvr injection)
• Xpovio (selinexor tablets)